Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer

Cancer Letters

Volumn 333, Issue 1, 2013, Pages 89-95

  Gocho, Takeshi ^a   Uwagawa, Tadashi ^a   Furukawa, Kenei ^a   Haruki, Koichiro ^a   Fujiwara, Yuki ^a   Iwase, Ryota ^a   Misawa, Takeyuki ^a   Ohashi, Toya ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Nafamostat mesilate; Nuclear factor B; Oxaliplatin; Pancreatic cancer

Indexed keywords

CASPASE 8; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NAFAMSTAT MESILATE; OXALIPLATIN; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; GUANIDINES; HUMANS; I-KAPPA B PROTEINS; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PHOSPHORYLATION;

EID: 84876080306     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.019     Document Type: Article

References (57)

1. American Cancer Society, Global Cancer Facts & Figures 2nd Edition, Atlanta, Ga, USA. (accessed 01.12.12). http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf.
2. American Cancer Society, Cancer Facts & figures 2012, Atlanta, Ga, USA. (accessed 12.10.12). http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
3. Sohn T.A., Yeo C.J., Cameron J.L., Koniaris L., Kaushal S., Abrams R.A., Sauter P.K., Coleman J., Hruban R.H., Lillemoe K.D. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indications. J. Gastrointest. Surg. 2000, 4:567-579.
4. Yeo T.P., Hruban R.H., Leach S.D., Wilentz R.E., Sohn T.A., Kern S.E., Iacobuzio-Donahue C.A., Maitra A., Goggins M., Canto M.I., Abrams R.A., Laheru D., Jaffee E.M., Hidalgo M., Yeo C.J. Pancreatic cancer. Curr. Probl. Cancer 2002, 26:176-275.
5. Niederhuber J.E., Brennan M.F., Menck H.R. The National Cancer Date Base report on pancreatic cancer. Cancer 1995, 76:91671-91677.
6. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Porteenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
7. Karin M., Lin A. NF-κB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
8. Rayet B., Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947.
9. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., Chiao P.J. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 1999, 5:119-127.
10. Arlt A., Schäfer H. NF kappa B-dependent chemoresistance in solid tumors. Int. J. Clin. Pharmacol. Ther. 2002, 40:336-347.
11. Fujioka S., Sclabas G.M., Schmidit C., Frederic W.A., Dong Q.G., Abbruzzese J.L., Evans D.B., Baker C., Chiao P.J. Function of nuclear factor κB in pancreatic cancer metastasis. Clin. Cancer. Res. 2003, 9:346-354.
12. Rakitina T.V., Vasilevskaya I.A., O'Dwyer P.J. Addictive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kB signaling. Cancer Res. 2003, 63:8600-8605.
13. Wilson C., Purcell C., Seaton A., Oladipo O., Maxwell P.J., O'Sullivan J.M., Wilson R.H., Johnston P.G., Waugh D.J. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of Nuclear Factor-κB transcription and evasion of apoptosis. J. Pharmacol. Exp. Ther. 2008, 327:746-759.
14. Banerjee S., Kaseb A.O., Wang Z., Kong D., Mohammad M., Padhye S., Sarkar F.H., Mohammad R.M. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 2009, 69:5575-5583.
15. Banerjee S., Wang Z., Kong D., Sarkar F.H. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2009, 69:5592-5600.
16. Fujioka S., Sclabas G.M., Schmidt C., Niu J., Frederick W.A., Dong Q.G., Abbruzzese J.L., Evans D.B., Baker C., Chiao P.J. Inhibition of constitutive NF-kappa B activity by IκBαM suppresses tumorigenesis. Oncogene 2003, 22:1365-1370.
17. Fujii S., Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, kallikrein and trypsin. Biochim. Biophys. Acta 1981, 661:342-345.
18. Iwaki M., Ino Y., Motoyoshi A., Ozeki M., Sato T., Kurumi M., Aoyama T. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn. J. Phamacol. 1986, 41:155-162.
19. Takahashi H., Takizawa S., Tatewaki W., Nagai K., Wada K., Hanano M., Shibata A. Nafamostat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulations. Thromb. Haemost. 1989, 62:372.
20. Ohtake Y., Hirasawa H., Sugai T., Oda S., Shiga H., Matsuda K., Kitamura N. Nafamostat mesilate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib. Nephrol. 1991, 93:215-217.
21. Uwagawa T., Li Z., Chang Z., Xia Q., Peng B., Sclabas G.M., Ishiyama S., Hung M.C., Evans D.B., Abbruzzese J.L., Chiao P.J. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer 2007, 109:2142-2153.
22. Furukawa K., Iida T., Shiba H., Fujiwara Y., Uwagawa T., Shimada Y., Misawa T., Ohashi T., Yanaga K. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model. Oncol. Rep. 2010, 24:843-850.
23. Uwagawa T., Chiao P.J., Gocho T., Hirohara S., Misawa T., Yanaga K. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-κB activation. Anticancer Res. 2009, 29:3173-3178.
24. Uwagawa T., Misawa T., Sakamoto T., Ito R., Gocho T., Shiba H., Wakiyama S., Hirohara S., Sadaoka S., Yanaga K. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann. Oncol. 2009, 20:239-243.
25. Uwagawa T., Misawa T., Tsutsui N., Ito R., GochoT, Hirohara S., Sadaoka S., Yanaga K. Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Am. J. Clin. Oncol. 2011, 9. (Epub ahead of print).
26. Fujiwara Y., Furukawa K., Shimada Y., Iida T., Shiba H., Uwagawa T., Misawa T., Ohashi T., Yanaga K. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer. Pancreas 2011, 40:600-607.
27. Fujiwara Y., Furukawa K., Haruki K., Shimada Y., Iida T., Shiba H., Uwagawa T., Ohashi T., Yanaga K. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer through nuclear factor kappa-B inhibition. J. Hepatobiliary Pancreat. Sci. 2011, 18:731-739.
28. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., André T., Zaniboni A., Ducreux M., Aitini E., Taïeb J., Faroux R., Lepere C., de Gramont A. GERCOR, GISCAD, Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005, 23:3509-3516.
29. Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardière C., Bennouna J., Bachet J.B., Khemissa-Akouz F., Péré-Vergé D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825.
30. Kidani Y., Inagaki K. Antitumor activity of 1,2-diaminocyclohexame-platinum complexes against sarcoma-180 ascites form. J. Med. Chem. 1978, 21:1315-1318.
31. Monnet I., Brienza S., Hugret F., Voisin S., Gastiaburu J., Saltiel J.C., Soulié P., Armand J.P., Cvitkovic E., de Cremoux H. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). Eur. J. Cancer 1998, 34:1124-1127.
32. Garufi C., Nisticò C., Brienza S., Vaccaro A., D'Ottavio A., Zappalà A.R., Aschelter A.M., Terzoli E. Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann. Oncol. 2001, 12:179-182.
33. Chollet P., Bensmaïne M.A., Brienza S., Deloche C., Curé H., Caillet H., Cvitkovic E. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann. Oncol. 1996, 7:1065-1070.
34. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Pitot H.C., Alberts S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004, 22:23-30.
35. Desoize B., Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol. 2002, 42:317-325.
36. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehmé A., Christen R.D., Howell S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56:4881-4886.
37. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., Hamilton T.C., Chaney S.G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998, 58:3579-3585.
38. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., Kawagoe J., Takahashi K., Yada-Hashimoto N., Seino-Noda H., Sakata M., Motoyama T., Kurachi H., Testa J.R., Tasaka K., Murata Y. Inhibition of inhibitor of nuclear factor-κB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin. Cancer Res. 2004, 10:7645-7654.
39. Bava S.V., Puliappadamba V.T., Deepti A., Nair A., Karunagaran D., Anto R.J. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J. Biol. Chem. 2005, 280:6301-6308.
40. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., Philip P.A., Abbruzzese J., Sarkar F.H. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005, 65:9064-9072.
41. Cusack J.C., Liu R., Xia L., Chao T.H., Pien C., Niu W., Palombella V.J., Neuteboom S.T., Palladino M.A. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res. 2006, 12:6758-6764.
42. Jani T.S., DeVecchio J., Mazumdar Tapati, Agyeman A., Houghton J.A. Inhibition of NF-κB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J. Biol. Chem. 2010, 285:19162-19172.
43. Fang L.J., Shao X.T., Wang S., Lu G.H., Xu T., Zhou J.Y. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-κB activation and induction of apoptosis. Planta. Med. 2010, 76:258-264.
44. Harikumar K.B., Kunnumakkara A.B., Sethi G., Diagaradjane P., Anand P., Pandey M.K., Gelovani J., Krishnan S., Guha S., Aggarwal B.B. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer 2010, 127:257-268.
45. Melisi D., Xia Q., Paradiso G., Ling J., Moccia T., Carbone C., Budillon A., Abbruzzese J.L., Chiao P.J. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J. Natl. Cancer Inst. 2011, 103:1190-1204.
46. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348:2609-2617.
47. Shah S.A., Potter M.W., McDade T.P., Ricciardi R., Perugini R.A., Elliott P.J., Adams J., Callery M.P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 2001, 82:110-122.
48. Abou-Alfa G.K., Letourneau R., Harker G., Modiano M., Hurwitz H., Tchekmedyian N.S., Feit K., Ackerman J., De Jager R.L., Eckhardt S.G., O'Reilly E.M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Olcol. 2006, 24:4441-4447.
49. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson A.B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002, 20:3270-3275.
50. Yeh P.Y., Chuang S.E., Yeh K.H., Song Y.C., Ea C.K., Cheng A.L. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement anticancer drug-induced NFκB activation. Biochem. Pharmacol. 2002, 63:1423-1430.
51. Wang W., McLeod H.L., Cassidy J. Disulfiram-mediated inhibition of NF-κB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int. J. Cancer 2003, 104:504-511.
52. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance. enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. 1999, 5:412-417.
53. Rothe M., Xiong J., Shu H.B., Williamson K., Goddard A., Goeddel D.V. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc. Natl. Acad. Sci. USA 1996, 93:8241-8246.
54. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190.
55. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
56. Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. USA 1997, 94:10057-10062.
57. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 2010, 10:561-574.